Immuneering Corp. (IMRX)
3.73
-0.08
(-2.10%)
USD |
NASDAQ |
Oct 23, 16:00
3.56
-0.17
(-4.56%)
After-Hours: 06:38
Immuneering Enterprise Value : 95.05M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 95.05M |
| October 22, 2026 | 100.23M |
| October 21, 2026 | 95.70M |
| October 20, 2026 | 95.05M |
| October 19, 2026 | 90.53M |
| October 16, 2026 | 86.00M |
| October 15, 2026 | 89.23M |
| October 14, 2026 | 75.00M |
| October 13, 2026 | 84.06M |
| October 12, 2026 | 103.47M |
| October 09, 2026 | 108.64M |
| October 08, 2026 | 95.70M |
| October 07, 2026 | 103.47M |
| October 06, 2026 | 101.52M |
| October 05, 2026 | 115.11M |
| October 02, 2026 | 117.05M |
| October 01, 2026 | 114.46M |
| September 30, 2026 | 118.67M |
| September 29, 2026 | 120.93M |
| September 28, 2026 | 122.87M |
| September 25, 2026 | 129.99M |
| September 24, 2026 | 134.52M |
| September 23, 2026 | 137.11M |
| September 22, 2026 | 151.99M |
| September 21, 2026 | 140.99M |
| Date | Value |
|---|---|
| September 18, 2026 | 143.58M |
| September 17, 2026 | 142.28M |
| September 16, 2026 | 141.64M |
| September 15, 2026 | 140.99M |
| September 14, 2026 | 133.87M |
| September 11, 2026 | 129.99M |
| September 10, 2026 | 149.40M |
| September 09, 2026 | 151.99M |
| September 08, 2026 | 162.99M |
| September 04, 2026 | 165.57M |
| September 03, 2026 | 179.81M |
| September 02, 2026 | 178.51M |
| September 01, 2026 | 167.52M |
| August 31, 2026 | 176.57M |
| August 28, 2026 | 176.57M |
| August 27, 2026 | 190.81M |
| August 26, 2026 | 186.92M |
| August 25, 2026 | 192.10M |
| August 24, 2026 | 188.87M |
| August 21, 2026 | 196.63M |
| August 20, 2026 | 193.39M |
| August 19, 2026 | 198.57M |
| August 18, 2026 | 179.16M |
| August 17, 2026 | 191.45M |
| August 14, 2026 | 181.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.27M |
| Total Expenses (Quarterly) | 17.27M |
| EPS Diluted (Quarterly) | -0.2669 |
| Earnings Yield | -27.66% |
| Normalized Earnings Yield | -27.66 |